Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Autonomix Medical, Inc. Common Stock (AMIX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
12/16/2024: AMIX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/16/2024 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.05M USD | Price to earnings Ratio - | 1Y Target Price 18 |
Price to earnings Ratio - | 1Y Target Price 18 | ||
Volume (30-day avg) 184737 | Beta - | 52 Weeks Range 1.52 - 75.80 | Updated Date 04/5/2025 |
52 Weeks Range 1.52 - 75.80 | Updated Date 04/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -17.23 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -97.67% | Return on Equity (TTM) -662.79% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -6639393 | Price to Sales(TTM) - |
Enterprise Value -6639393 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 2462980 | Shares Floating 2078905 |
Shares Outstanding 2462980 | Shares Floating 2078905 | ||
Percent Insiders 19.52 | Percent Institutions 19.89 |
Analyst Ratings
Rating 5 | Target Price 28 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Autonomix Medical, Inc. Common Stock
Company Overview
History and Background
Autonomix Medical, Inc. is a medical device company focused on developing innovative technologies for minimally invasive nerve ablation procedures. Details on founding year and early milestones are not readily available in standard financial databases.
Core Business Areas
- Nerve Ablation Technology: Focuses on developing and commercializing devices for targeted nerve ablation to treat chronic pain and other conditions.
Leadership and Structure
Information on specific leadership team and detailed organizational structure is not available in standard financial databases.
Top Products and Market Share
Key Offerings
- Autonomix System: Autonomix is developing the Autonomix System, a robotic micro-surgical system designed to target and ablate specific nerves. Market share data and revenue figures are currently not publicly available as the product is still under development. Competitors include companies developing similar nerve ablation technologies (e.g., Medtronic, Boston Scientific) and companies using alternative pain management techniques.
Market Dynamics
Industry Overview
The medical device industry, specifically the pain management sector, is experiencing growth driven by an aging population and increasing demand for minimally invasive procedures.
Positioning
Autonomix Medical aims to position itself as a leader in precision nerve ablation technology with its robotic micro-surgical system.
Total Addressable Market (TAM)
The total addressable market for chronic pain management is significant, estimated in the billions of dollars. Autonomix is aiming to capture a portion of this market through its innovative technology; TAM specific to their exact focus is not readily available. It is positioned to address a specific niche within the broader pain management market.
Upturn SWOT Analysis
Strengths
- Innovative technology with potential for improved precision and reduced invasiveness
- Focus on a specific unmet need in chronic pain management
- Potential for significant market disruption
Weaknesses
- Limited operating history and commercialization experience
- Dependence on regulatory approvals and clinical trial success
- High risk of failure due to early stage development
Opportunities
- Expanding applications of nerve ablation technology
- Partnerships with larger medical device companies
- Increasing prevalence of chronic pain conditions
Threats
- Competition from established medical device companies
- Regulatory hurdles and delays
- Technological obsolescence
Competitors and Market Share
Key Competitors
- MDT
- BSX
- ABT
Competitive Landscape
Autonomix Medical faces strong competition from established medical device companies with extensive resources and market presence. Its success depends on its ability to differentiate its technology and demonstrate clinical efficacy.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: N/A
Future Projections: Future projections are uncertain and depend on the successful development and commercialization of its technology. Analyst estimates are not readily available.
Recent Initiatives: Focus on completing clinical trials and securing regulatory approvals for its Autonomix System.
Summary
Autonomix Medical is an early-stage company with innovative technology in the nerve ablation space. Its success hinges on completing clinical trials and securing regulatory approval. While the potential market is large, it faces significant competition and risks associated with early-stage development. The company needs to focus on de-risking its technology and securing partnerships to accelerate its growth.
Similar Companies
ABT
Abbott Laboratories
ABT
Abbott Laboratories
BSX
Boston Scientific Corp
BSX
Boston Scientific Corp
MDT
Medtronic PLC
MDT
Medtronic PLC
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Industry Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investing in early-stage companies involves significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Autonomix Medical, Inc. Common Stock
Exchange NASDAQ | Headquaters The Woodlands, TX, United States | ||
IPO Launch date 2024-01-29 | CEO & President Mr. Bradley Hauser | ||
Sector Healthcare | Industry Medical Devices | Full time employees 5 | Website https://autonomix.com |
Full time employees 5 | Website https://autonomix.com | ||
Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders. It has an agreement with NoiseFigure Research, Inc. to develop next generation of its proprietary microchip. Autonomix Medical, Inc. was incorporated in 2014 and is based in The Woodlands, Texas.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.